Discovery and Biological Signatures of Diet-Derived Microbial Metabolites (R01 Clinical Trial Optional)Evidence is building that low molecular weight compounds, derived from interaction of dietary constituents and other natural products with the gut microbiome, have important biological activity. The purpose of this Funding Opportunity Announcement (FOA), therefore, is to identify metabolites produced by the interaction between commensal bacteria and dietary phytochemicals and characterize their biological activity. This FOA will support both model systems research and mechanistic clinical studies. Application Due Date: March 19, 2018 by 5:00 PM local time of applicant organization. |
Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
martes, 26 de diciembre de 2017
RFA-AT-18-003: Discovery and Biological Signatures of Diet Derived Microbial Metabolites (R01 Clinical Trial Optional)
RFA-AT-18-003: Discovery and Biological Signatures of Diet Derived Microbial Metabolites (R01 Clinical Trial Optional)


No hay comentarios:
Publicar un comentario